An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals

Background. Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade gliomas (HGG) in phase II clinical trials. Patients and Methods. Data were collected from patients with recurrent HGG who initiated treatment wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Huylebrouck, M., Lv, S., Duerinck, J., Van Binst, A., Salmon, I., De Greve, J., De Witte, O., Luce, S., Michotte, A., D'Haens, J., Neyns, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317219/
https://www.ncbi.nlm.nih.gov/pubmed/22481934
http://dx.doi.org/10.1155/2012/801306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317219/
https://www.ncbi.nlm.nih.gov/pubmed/22481934
http://dx.doi.org/10.1155/2012/801306

Ejemplares similares